Literature DB >> 12920861

Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor.

Rick V Hay1, Brian Cao, R Scot Skinner, Ling-Mei Wang, Yanli Su, James H Resau, George F Vande Woude, Milton D Gross.   

Abstract

Inappropriate expression of the c-met-protooncogene product (Met) and/or of its ligand, hepatocyte growth factor/scatter factor (HGF/SF), has been correlated with poor prognosis in a variety of human solid tumors. We are developing animal models for nuclear imaging of Met and HGF/SF expression in tumors in vivo. We radioiodinated a mixture of monoclonal antibodies (MAbs) that bind to human HGF/SF and to the external ligand-binding domain of human Met, and then injected the I-125-MAb mixture intravenously into mice bearing tumors either autocrine for human HGF/SF and human Met or autocrine-paracrine for murine HGF/SF and murine Met. Serial total body gamma camera images were obtained, and regional activity was determined by quantitative region-of-interest (ROI) analysis. Tumors autocrine for human HGF/SF and Met demonstrated significantly more rapid uptake and more rapid clearance of the I-125-MAb mixture than tumors expressing one or both murine homologues, reaching a mean tumor to total body activity ratio of > 0.3 by 1 day postinjection. We conclude that radioimmunodetection of tumors autocrine for human HGF/SF and Met is feasible with an I-125-MAb mixture reactive against the ligand-receptor pair.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12920861     DOI: 10.1162/153535002753395716

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  7 in total

1.  Noninvasive real-time imaging of apoptosis.

Authors:  Bharathi Laxman; Daniel E Hall; Mahaveer Swaroop Bhojani; Daniel A Hamstra; Thomas L Chenevert; Brian D Ross; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-10       Impact factor: 11.205

2.  Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library.

Authors:  Yongjun Jiao; Ping Zhao; Jin Zhu; Tessa Grabinski; Zhengqing Feng; Xiaohong Guan; R Scot Skinner; Milton D Gross; Rick V Hay; Hiroshi Tachibana; Brian Cao
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

Review 3.  Emerging trends for radioimmunotherapy in solid tumors.

Authors:  Maneesh Jain; Suprit Gupta; Sukhwinder Kaur; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Cancer Biother Radiopharm       Date:  2013-07-11       Impact factor: 3.099

Review 4.  Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review.

Authors:  Zhaoguo Han; Yongyi Wu; Kai Wang; Yadi Xiao; Zhen Cheng; Xilin Sun; Baozhong Shen
Journal:  EJNMMI Res       Date:  2017-05-08       Impact factor: 3.138

Review 5.  Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography.

Authors:  Giuseppe Floresta; Vincenzo Abbate
Journal:  Med Res Rev       Date:  2022-03-16       Impact factor: 12.388

6.  A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Authors:  Beatrice S Knudsen; Ping Zhao; James Resau; Sandra Cottingham; Ermanno Gherardi; Eric Xu; Bree Berghuis; Jennifer Daugherty; Tessa Grabinski; Jose Toro; Troy Giambernardi; R Scot Skinner; Milton Gross; Eric Hudson; Eric Kort; Ernst Lengyel; Aviva Ventura; Richard A West; Qian Xie; Rick Hay; George Vande Woude; Brian Cao
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

7.  Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies.

Authors:  W G Jiang
Journal:  Curr Oncol       Date:  2007-04       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.